John Evans is the Chief Executive Officer of Beam Therapeutics Inc., a leading biotechnology company focused on developing precision genetic medicines through base editing. With a robust background in the biopharmaceutical industry, John has played a pivotal role in steering Beam Therapeutics towards groundbreaking advancements in gene editing technologies. Prior to joining Beam, John held significant leadership positions that honed his expertise in drug development and corporate strategy. Before becoming CEO of Beam Therapeutics, John served as the President and Chief Executive Officer of Intellia Therapeutics, another prominent gene editing company, where he successfully led the organization through its early stages of development and into clinical trials. His tenure at Intellia was marked by strategic partnerships and significant fundraising efforts that propelled the company forward. John's earlier career also includes a notable stint at Biogen, where he held various senior roles, including Senior Vice President of Global Neurology, demonstrating his deep understanding of the complexities involved in bringing innovative therapies to market. As CEO of Beam Therapeutics, John Evans is responsible for overseeing the company's strategic direction and operational execution. Under his leadership, Beam has made significant strides in advancing its base editing platform, which promises to offer more precise and safer genetic modifications compared to traditional gene editing methods. John's vision for the company is centered on translating scientific breakthroughs into life-changing treatments for patients with serious genetic diseases. His leadership has been instrumental in fostering a culture of innovation and collaboration at Beam, positioning the company as a frontrunner in the rapidly evolving field of genetic medicine.